NCT00700882 2023-07-03
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
6 trialsNCT01876212 2019-08-22
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
University of Pittsburgh
Phase 2 Completed
NCT00608361 2015-07-02
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00563290 2015-06-18
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436605 2014-05-15
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00597038 2013-12-16
A Phase I/II Study of Dasatinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed